SILO (Silo Pharma Inc.) Net earnings per one share for the last twelve months

Silo Pharma (SILO) - corporate logo

Silo Pharma, Inc. (SILO) possesses significant market influence due to its innovative psilocybin transdermal patches for combating Alzheimer's disease. The annual volatility of TTM net income per share clearly demonstrates the dynamics of this process, where the mark 73.30 characterizes this parameter. Silo Pharma, Inc. (SILO) strictly adheres to ESG standards for chemical disposal, although its financial stability currently relies solely on raised investments without a stable cash flow.

silopharma.com (SILO) Net earnings per share (EPS TTM): for the period 02/11/2024 - 11/17/2026

SILO (Silo Pharma Inc.): analytical breakdowns and indicator data

- market price and analyst price targets:
- business market valuation indicators:
Fundamental company valuation:SILO (Silo Pharma Inc.)
Core merchandise of Silo Pharma

To select high-quality assets, investors filter out market noise through earnings analysis. This indicator measures the rolling annual growth of net income per share to determine real operational efficiency. For Silo Pharma, Inc. (SILO), the trend of this metric reflects the monetization value of patents and the success of clinical trials for the psilocybin patch. The volatility of EPS YoY over the last 12 months visualizes the financial stability of the biotech developments. An upward curve confirms business scalability, while a decline signals risks.